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METHODS: We used a non-parametric approach
employing Monte Carlo simulation to determine the
expected value of perfect information (EVPI) for the full
model and for a particular model parameter (probability
of resistance). We incorporated empiric distributions 
of the net beneﬁts associated with each treatment for
patients found to have sensitive and resistant bacteria (4
distributions for each model) created from 1,000 boot-
strap replications of the mean cost and effect. The boot-
strap replicates involved resampling from original cost
and effect data about 210 patients of whom 47 had 
bacteria resistant to TMP/SMX. In the base case the net
beneﬁts were constructed from the mean cost and effect
pairs by re-scaling the effects into a monetary value
assuming a societal willingness-to-pay $200 to prevent
one failure of treatment for pylonephritis. The model for
the population assumed an incidence of 0.4% per annum
for pyelonephritis in the US and UK and that the decision
would be valid for 10 years. 
RESULTS: Ciproﬂoxacin is the a priori choice because 
it is associated with the maximum net beneﬁt for each
diagnostic scenario for each diagnostic setting in the
model. Nonetheless, there is still residual uncertainty and
the EVPI for the decision is $2.18m for the US and £1.65
m in the UK. However, the partial evaluation revealed
that the EVPI for the prevalence of resistance is only
$3,048 in the US and £1,876 in the UK. 
CONCLUSIONS: Uncertainty about the prevalence of
resistance makes a minor contribution to the overall EVPI
for the decision.
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OBJECTIVES: The prevalence of Neisseria gonnorrhoeae
(GC) among adolescents and young women attending
urban emergency rooms (ER) ranges from 3% to 10%
but screening has historically not been feasible in this
setting. Our objective was to assess the cost-effectiveness
of newer technologies that bypass the need for a pelvic
exam and reduce loss to follow-up.
METHODS: We developed a state-transition Markov
model of the natural history of GC and simulated screen-
ing, diagnosis, and treatment in a cohort of 10,000 15-
year-old U.S. women. Adopting a societal perspective, we
compared no screening to selective age-based screening
using either the: 1) ligase chain reaction (LCR) on a urine
sample; or 2) rapid immunochromotographic assay (RIA)
on a clinician-collected vaginal sample. We assumed 80%
of LCR screen-positive women would be treated (20%
loss to follow-up) and 100% of RIA screen-positive
women would receive immediate treatment. We assumed
a peak GC prevalence of 6%. Clinical outcomes included
cases of GC, pelvic inﬂammatory disease (PID), major
PID sequelae, and quality-adjusted life expectancy
(QALE). Economic outcomes included incremental cost-
effectiveness ratios (cost per quality-adjusted life year
saved). Data were obtained from population-based
studies, national databases and published literature.
RESULTS: Compared to no screening, screening women
aged 15 to 24 with RIA was more effective and cost-
effective (i.e., dominated) than LCR and cost $1,850 per
QALY. Provided the RIA assay (base case $20) was less
than $100, the cost-effectiveness ratio for screening with
the rapid test was less than $10,000 per QALY. Results
were stable despite varying the prevalence of GC, direct
medical costs, and quality of life weights over a wide
plausible range.
CONCLUSIONS: Screening for GC within an urban-ER
setting using the new RIA test facilitates rapid screening
and treatment and has a cost-effectiveness ratio that is
more attractive than many current preventive health
interventions.
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OBJECTIVE: Brazil’s universal access to HIV treatment
and drug price reductions have affordably treated large
segments of the country’s HIV-infected population.
Several countries in Central America have large HIV-
infected populations without access to care. This analy-
sis examines the feasibility of applying Brazil’s universal
access to treatment and drug price reductions given the
economic conditions in three Central American countries:
Guatamala (n = 71,050), El Salvador (n = 19,400), and
Belize (n = 2,400). 
METHODS: Each country’s HIV population not 
currently receiving antiretroviral therapy was estimated.
For each population, the cost of two-drug and three-drug
combination antiretroviral therapy was estimated by
applying 2000 Brazilian prices (in U.S. dollars). The ratio
of drug costs to gross domestic product was determined
to measure each country’s relative ability to pay for 
the cost of treatment. The Brazilian rate of cost savings
from averted hospitalizations was subtracted from each
country’s drug cost estimates to determine total cost of
treatment. 
RESULTS: In Guatamala, the drug costs for treating the
HIV population ranges between $54.2 (0.117% of GDP)
and $335.1 (0.725%) million depending on whether
double or triple combination therapy is used. The costs
range between $14.8 (0.062%) and $91.5 (0.381%)
million in El Salvador, and between $1.8 (0.232%) and
$11.3 (1.433%) in Belize. Potential hospitalization costs
averted were $80.5 million in Guatamala, $22.0 million
in El Salvador, and $2.7 million in Belize. Given these
costs averted, the total cost of treatment ranges between
-$28.5 (cost savings) and $252.4 million in Guatamala
depending on whether double or triple combination
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therapy is used, between -$7.9 and $68.8 million in El
Salvador, and between -$888.8 thousand and $8.6
million in Belize. 
CONCLUSIONS: Since the ratio of antiretroviral drug
costs to GDP was 0.041% in Brazil in 2000, these three
Central American countries may have more difﬁculty
affording antiretroviral therapy unless double combina-
tion therapy is used.
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OBJECTIVE: An issue that has recently received atten-
tion from health economists is how to handle the problem
of missing data in stochastic cost-effectiveness analysis.
The purpose of this paper is to highlight the impact 
that different approaches to the imputation of missing
data can have on estimates of the physical quantities of
medical care resource use. 
METHODS: Medical care resource use data were 
collected prospectively in a 6-month RCT comparing 
two treatments for a chronic condition that is charac-
terised by acute episodes. Two approaches of the 
multiple imputation were used to address the problem of
missing data. Method A relied on imputing missing data
for total costs and then estimating the physical quantities
of medical care resource use. Method B relied on imput-
ing missing data for the physical quantities of medical
care resource use and then estimating total costs. Results
for physician and nurse visits and days in the hospital
were reported. 
RESULTS: The two multiple imputation approaches 
produced different estimates of medical care resource use.
For method A, the average number of physician and nurse
visits and days in the hospital between the two groups
were 5.7 vs. 5.3 physician visits, 1.0 vs. 0.9 nurse visits,
and 4.0 vs. 4.7 days in the hospital. For method B the
average number of physician and nurse visits and days 
in the hospital between the two groups were 6.0 vs. 6.3
physician visits, 1.2 vs. 1.3 nurse visits, and 4.0 vs. 5.0
days in the hospital. 
CONCLUSIONS: Medical care resource use estimates are
sensitive to the imputation approach. Method B builds
prediction models speciﬁcally for the utilisation compo-
nents under the imputation and results from the imputed
datasets are believed to be less biased. It also provides
more ﬂexibility for analysing the cost components.
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The US Public Health Service Panel on Cost-Effectiveness
issued a series of recommendations designed to improve
the rigor and consistency of cost-effectiveness analyses.
While the Panel’s individual recommendations are largely
sound, they nevertheless vary in importance. That is, the
violation of some recommendations will yield dramati-
cally different cost-effectiveness estimates and resource
allocation decisions than the violation of other 
recommendations. 
OBJECTIVE: The Panel has advocated the use of quality-
adjusted life-years (QALYs) as the best way to evaluate
outcomes in a cost-effectiveness analysis. We consider the
importance of this recommendation for cancer preven-
tion, screening, and treatment by studying the empirical
relationship between cost/life-year and cost/QALY. In
addition, we consider whether adjusting for health-
related quality of life (QOL) affects the ultimate resource
allocation decision implied by the cost-effectiveness ratio. 
METHODS: We identiﬁed 198 articles reporting two 
or more outcome measures for the same intervention:
cost/life-year, cost/QALY, total life-years, total QALYs,
incremental life-years, or incremental QALYs. We calcu-
lated a correlation matrix for these outcomes and per-
formed a regression analysis to examine the relationship
between cost/life-year and cost/QALY. We also employed
various willingness to pay (WTP) thresholds to assess
whether the use of cost/life-year would yield different
resource allocation decisions than cost/QALY. 
RESULTS: The correlation between the total life-years
and total QALYs associated with the intervention is 0.97
(P < 0.0001). The correlation between cost/life-year and
cost/QALY is 0.78 (P < 0.0001). Assuming a $50,000
WTP threshold, adjustment for QOL would affect choice
in 7% of cases. With a $400,000 threshold, QOL would
affect choice in 2% of cases. 
CONCLUSION: The outcome measures of life-years and
QALYs are highly correlated with one another. While
adjusting for QOL can make an important difference 
in some economic analyses, it generally does not affect
implied resource allocation decisions for cancer preven-
tion, screening, and treatment.
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